People: Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

102.20CHF
5:28am EDT
Price Change (% chg)

CHF0.20 (+0.20%)
Prev Close
CHF102.00
Open
CHF102.00
Day's High
CHF102.50
Day's Low
CHF100.80
Volume
157,648
Avg. Vol
460,723
52-wk High
CHF115.50
52-wk Low
CHF66.50

Search Stocks

Clozel, Jean-Paul 

Brief Biography

Mr. Jean-Paul Clozel has been Chief Executive Officer, Member of the Executive Committee and Delegate to the Board of Directors of Actelion Ltd since April 2000. He has acted as Chief Financial Officer of the Company since 1999. Mr. Clozel was a practicing cardiologist from 1974 till 1985. He served as Head of Drug Discovery Group in Cardiovascular Department of F. Hoffmann-La Roche from 1985 to 1997, where he was responsible for the selection of T-channel blocker. He also participated in the characterization of renin inhibitors, as well as several endothelin receptor antagonists such as bosentan and clazosentan. He has developed various, novel experimental models allowing the differentiation of these drugs. This work was honored with the 1997 Hoffmann-La Roche Research Prize. In 2007, he was nominated professor at the College de France in Paris and as Chair of Technical Innovation. He obtained a medical degree in France and has further training in pharmacology and psychology at the University of Montreal and the University of California.

Basic Compensation

Total Annual Compensation, CHF Long-Term Incentive Plans, CHF All Other, CHF Fiscal Year Total, CHF
4,470,180 -- 710,748 5,180,920

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Search Stocks